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Introduction
In recent years, polypharmacology has gained popularity in drug dis-
covery [1]. Especially for complex diseases such as cancer, the ability 
of a drug to bind to and interfere with multiple targets provides new 
opportunities for therapeutic intervention. In this article, we focus on 
Hsp90 and its interactome, whose pivotal role in survival and prolifera-
tion of cancer cells renders this array of targets particularly attractive 
for polypharmacological drug design strategies.
The primary goal of our work is the identification and selection of suit-
able target proteins from the interactome that might be combined with 
Hsp90 to explore and exploit a multi-target inhibition approach. This 
task is accomplished by applying computational methods to mine the 
structural and biological information associated with potential ligands 
in public databases and assess the degree of structural similarity be-
tween known inhibitors of different targets. Therefore, we propose 
an integrated ligand- and structure-based approach to select small 
molecules from databases suitable for consideration as multi-target 
inhibitors.
Biological background
Cancer is one of the world leading causes of death accounting for 
7.6 million deaths in the year 2008. The number of deaths per year is 
projected to rise to 13.1 million in 2030 [2]. Both genetic and environ-
mental factors may be at the origin of human cancers. In general, can-
cer cells are characterized by uncontrolled proliferation and survival. 
Indeed, several cellular pathways might be affected by this pathology 
contributing to the expression of the transformed phenotype. Heat 
shock response is often activated in cancer cells, contributing to both 
initiation and maintenance of the transformed phenotype. Hsp90 is an 
important component of this process, acting as a molecular chaper-
one affecting stability and activation of more than 200 client proteins 
through ATP hydrolysis cycles [3]. Proteins interacting with Hsp90 are 
often involved in signalling processes, such as transcription factors 
and kinases.
Polypharmacology and Hsp90
Popular computational methods applied in medicinal chemistry include 
ligand- and structure-based virtual screening. These techniques aim 
at finding new small organic molecules with specific activity against a 
given biological target. Typically, the target is a protein that might act 
as an enzyme, a receptor, or an ion-channel, whose activity is involved 
in a pathological mechanism. The interaction of the small molecule 
with the target is intended to interfere with the protein’s activity in a 
physiologically relevant manner. Following the classical drug design 
paradigm, the small molecule should be highly selective for the cho-
sen target. Interactions with additional targets might be the cause of 
the so called off-target effects, which in turn might be responsible for 
toxicity and thus impair the development of a safe, marketable drug.
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Hsp90 and its interactome represent an attractive array of targets for polypharmacological drug design strategies in cancer therapy. 
In this work, we propose a computational protocol aimed at the selection of promising target combinations and potential multi-target 
active compounds.
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Schematic representation of the aim of the project: use of combined 
ligand- and structure-based virtual screening techniques to 
discover potential multi-target inhibitors of the Hsp90 interactome
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Approcci polifarmacologici in silico mirati all’interattoma di Hsp90
Hsp90 ed il suo interattoma sono bersagli attraenti per l’applicazione di strategie polifarmacologiche nella terapia antitumorale. In questo studio viene proposto 
un protocollo computazionale mirato alla selezione di combinazioni promettenti di bersagli e di potenziali composti attivi su bersagli multipli.
RIASSUNTO
The idea of targeting multiple proteins involved in a given pathol-
ogy was initially applied by prescribing multiple drugs in combination 
therapies. Nevertheless, some drugs initially designed to be target-
selective have been proven later on to exert their therapeutic activity 
through the simultaneous interaction with multiple targets. Hence, 
the paradigm of trying to design drugs acting on a single target has 
recently been extended by the concept of polypharmacology, which 
aims at rationally develop therapeutic agents that interact simultane-
ously with multiple targets. In principle, this approach has the advan-
tage that it could cause an improved therapeutic effect and bypass 
complications associated with the prescription of two or more drugs 
in combination therapies. Designing compounds acting on multi-
ple targets is a complex task but, if successful, might often lead to 
more efficient drugs (in therapeutic areas where target specificity is 
not a stringent requirement). In this context, a key question is which 
combination(s) of targets should best be considered for a polyphar-
macology approach to treat a particular disease.
Given the pivotal role on Hsp90 in cancer, the development of Hsp90 
inhibitors has long been a major focal point in oncological drug dis-
covery [4, 5]. The most important chemical classes of Hsp90 in-
hibitors include, among others, ansamycins, resorcinol derivatives, 
purines, imidazopyridines, oxazoles. Fourteen drug candidates tar-
geting Hsp90 are now undergoing clinical trials, but none of them has 
as of yet achieved market approval.
Because Hsp90 is a key node in many biological networks and inter-
acts with a very large number of client proteins and co-chaperones 
[4], this target and its interactome are thought to be highly relevant for 
polypharmacology approaches. However, polypharmacological ap-
proaches to target Hsp90 are still largely unexplored.
Workflow and results
For rational polypharmacological ligand design targeting the the 
Hsp90 interactome, a computational procedure has been designed 
that consists of several steps, the first of which is an activity annota-
tion analysis in public compound databases to collect known inhibi-
tors of Hsp90 and its client proteins.
So identified inhibitors have been used as templates for ligand-based 
virtual screening of the ChEMBL [6] and ZINC [7] databases. Then, 
the analysis of the top-ranked database compounds taking activity 
annotations as well as implications of their targets in cancer into ac-
count led to the selection of most promising candidates for interfer-
ence with Hsp90 in combination with secondary targets. For each 
target combination selected, a focused compound library has been 
built with the purpose of finding new multi-target active compounds 
without any known target annotation. Finally, structure-based virtual 
screening of these focused libraries against Hsp90 and the second-
ary targets has been carried out to further refine the selection and 
evaluate more thoroughly the potential affinity of pre-selected com-
pounds.
Conclusions
The analyses conducted so far suggest that public molecular da-
tabases contain a wealth of information about compounds active 
against the Hsp90 interactome. We have analyzed this information 
comprehensively and utilized it to design a computational polyphar-
macological approach. Following our approach, suitable target com-
binations have been identified and integrated ligand- and structure-
based virtual screening applied to identify candidate compounds 
for multi-target inhibition. Importantly, our computational approach 
to Hsp90 polypharmacology will be complemented by experimental 
evaluation of candidates and subsequent iterations of integrated vir-
tual screening.
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